Cart
sales@molnova.com
Fuzapladib
CAS No. 141283-87-6
Fuzapladib( —— )
Catalog No. M35957 CAS No. 141283-87-6
Fuzapladib (IS-741) (IS-741) is a phospholipase A2 inhibitor that can inhibits the expression of Mac-1, a cell adhesion molecule.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 186 | In Stock |
|
| 5MG | 141 | In Stock |
|
| 10MG | 212 | In Stock |
|
| 25MG | 448 | In Stock |
|
| 50MG | 639 | In Stock |
|
| 100MG | 830 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameFuzapladib
-
NoteResearch use only, not for human use.
-
Brief DescriptionFuzapladib (IS-741) (IS-741) is a phospholipase A2 inhibitor that can inhibits the expression of Mac-1, a cell adhesion molecule.
-
DescriptionFuzapladib (IS-741), an orally active leukocyte-function-associated antigen type 1 (LFA-1) activation inhibitor, is a leukocyte adhesion molecule. Fuzapladib is also a phospholipase A2 (PLA2) inhibitor. Fuzapladib exerts anti-inflammatory effects by inhibiting leukocyte migration into the inflammatory site.
-
In Vitro——
-
In VivoAnimal Model:RatsDosage:50 mg/kg Administration:P.o.; for 7 days Result:Significantly reduced myeloperoxidase (MPO) activity and mucosal IL-8 levels in rat ileum, reduced polymorphonuclear cells and Mac-1 positivity Infiltration of cells into inflammatory lesions, effectively alleviated trinitrobenzenesulfonic acid (TNBS)-induced ileitis.
-
Synonyms——
-
PathwayMetabolic Enzyme/Protease
-
TargetPhospholipase
-
RecptorPhospholipase
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number141283-87-6
-
Formula Weight379.4
-
Molecular FormulaC15H20F3N3O3S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (263.57 mM; Ultrasonic )
-
SMILESN(C(=O)C1CCCCC1)C2=C(NS(CC)(=O)=O)N=CC(C(F)(F)F)=C2
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Noriyuki Kaji, et al. Fuzapladib reduces postsurgical inflammation in the intestinal muscularis externa. J Vet Med Sci. 2023 Sep 21.?
molnova catalog
related products
-
LEI110
LEI110 is a potent Phospholipase A2, group XVI (PLA2G16) inhibitor with an Ki value of 20 nM. LEI110 is a selective pan-inhibitor of the HRASLS family of thiol hydrolases (i.e., PLA2G16, HRASLS2, RARRES3 and iNAT).
-
IACS-13909
IACS-13909, a specific and potent allosteric inhibitor of SHP2, that suppresses signaling through the MAPK pathway.
-
AK106-001616
AK106-001616 (AK 106-001616) is a potent and selective inhibitor of cytosolic phospholipase A2 (cPLA2) with IC50 of 3.8 nM (human cPLA2 enzyme).
